How do I see the production of engineered blood cells available for transfusion?

The in vitro production of red blood cells and platelets is a groundbreaking technology that can—when optimized—surrogate for donated blood cells, in total or in part. Here we discuss questions that may arise when the technology is available, relative to safety issues (comprising both quantitative a...

Descripción completa

Detalles Bibliográficos
Autor principal: Garraud, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323659/
https://www.ncbi.nlm.nih.gov/pubmed/32631500
http://dx.doi.org/10.1016/j.transci.2020.102863
_version_ 1783551810174189568
author Garraud, Olivier
author_facet Garraud, Olivier
author_sort Garraud, Olivier
collection PubMed
description The in vitro production of red blood cells and platelets is a groundbreaking technology that can—when optimized—surrogate for donated blood cells, in total or in part. Here we discuss questions that may arise when the technology is available, relative to safety issues (comprising both quantitative and qualitative parameters) and to ethics, an item often forgotten in the debates so far.
format Online
Article
Text
id pubmed-7323659
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-73236592020-06-30 How do I see the production of engineered blood cells available for transfusion? Garraud, Olivier Transfus Apher Sci Article The in vitro production of red blood cells and platelets is a groundbreaking technology that can—when optimized—surrogate for donated blood cells, in total or in part. Here we discuss questions that may arise when the technology is available, relative to safety issues (comprising both quantitative and qualitative parameters) and to ethics, an item often forgotten in the debates so far. Elsevier Ltd. 2020-08 2020-06-29 /pmc/articles/PMC7323659/ /pubmed/32631500 http://dx.doi.org/10.1016/j.transci.2020.102863 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Garraud, Olivier
How do I see the production of engineered blood cells available for transfusion?
title How do I see the production of engineered blood cells available for transfusion?
title_full How do I see the production of engineered blood cells available for transfusion?
title_fullStr How do I see the production of engineered blood cells available for transfusion?
title_full_unstemmed How do I see the production of engineered blood cells available for transfusion?
title_short How do I see the production of engineered blood cells available for transfusion?
title_sort how do i see the production of engineered blood cells available for transfusion?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323659/
https://www.ncbi.nlm.nih.gov/pubmed/32631500
http://dx.doi.org/10.1016/j.transci.2020.102863
work_keys_str_mv AT garraudolivier howdoiseetheproductionofengineeredbloodcellsavailablefortransfusion

Ejemplares similares